Brainstem glioma

Last updated
Brainstem glioma
Tumor BrainstemGlioma1.JPG
Brain stem glioma. MRI axial, with contrast
Specialty Oncology
Classification of brainstem gliomas by MRI appearance. Classification of brainstem gliomas by MRI appearance - Fonc-02-00205-g001.jpg
Classification of brainstem gliomas by MRI appearance.
Histopathology of a brainstem glioma. Histologic geographic variability of diffuse intrinsic pontine glioma (DIPG) - Fonc-02-00205-g003 D (cropped).jpg
Histopathology of a brainstem glioma.

A brainstem glioma is a cancerous glioma tumor in the brainstem. Around 75% are diagnosed in children and young adults under the age of twenty, but have been known to affect older adults as well. [1] Brainstem gliomas start in the brain or spinal cord tissue and typically spread throughout the nervous system. [2]

Contents

Classification

In children, brainsteam gliomas are classified as either diffuse intrinsic pontine gliomas (DIPGs) or as focal brain stem gliomas. The latter type are less aggressive and easier to treat. [3]

Signs and symptoms

Common symptoms include, but are not necessarily limited to:

Symptoms can develop slowly and subtly and may go unnoticed for months. In other cases, the symptoms may arise abruptly. A sudden onset of symptoms tends to occur with more rapidly growing, high-grade tumors.[ citation needed ]

Cause

The cause is still unknown. Researchers have not found any direct genetic link.

Diagnosis

Neuroimaging, such as MRI, is the main diagnostic tool for brain stem gliomas. In very rare cases, surgery and biopsy are performed.

Treatment

Unlike most brain tumors, brainstem glioma is not often treated with neurosurgery due to complications in vital parts of the brain. More often, it is treated with chemotherapy and/or radiation therapy (though past use of radiation therapy has yielded mixed results). [4]

However, these treatments do produce side effects; most often including nausea, the breakdown of the immune system, and fatigue. Hair loss can occur from both chemotherapy and radiation, but usually grows back after chemotherapy has ceased. Steroids such as Decadron may be required to treat swelling in the brain. Decadron can lead to weight gain and infection. Patients may also experience seizures, which need to be treated to avoid complications. For some patients there is a chance of a neurological breakdown; this can include, but is not limited to, confusion and memory loss. [5]

The use of topotecan has been investigated. [6]

There are several new[ when? ] clinical trials in process. One such trial is dendritic cell immunotherapy which uses the patient's tumor cells and white blood cells to produce a chemotherapy that directly attacks the tumor.[ citation needed ]

Prognosis

The prognosis for children depends on the tumor type; most children with DIPGs live less than 18 months whereas the survival time for most children with focal gliomas is more than 18 months. [3]

Research directions

Related Research Articles

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Glioma</span> Tumour of the glial cells of the brain or spine

A glioma is a type of primary tumor that starts in the glial cells of the brain or spinal cord. They are cancerous but some are extremely slow to develop. Gliomas comprise about 30 percent of all brain tumors and central nervous system tumours, and 80 percent of all malignant brain tumours.

<span class="mw-page-title-main">Oligodendroglioma</span> Medical condition

Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell. They occur primarily in adults but are also found in children.

<span class="mw-page-title-main">Glioblastoma</span> Aggressive type of brain cancer

Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has a very poor prognosis for survival. Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.

<span class="mw-page-title-main">Astrocytoma</span> Medical condition

Astrocytoma is a type of brain tumor. Astrocytomas originate from a specific kind of star-shaped glial cell in the cerebrum called an astrocyte. This type of tumor does not usually spread outside the brain and spinal cord and it does not usually affect other organs. After glioblastomas, astrocytomas are the second most common glioma and can occur in most parts of the brain and occasionally in the spinal cord.

<span class="mw-page-title-main">Desmoplastic small-round-cell tumor</span> Aggressive and rare cancer

Desmoplastic small-round-cell tumor (DSRCT) is an aggressive and rare cancer that primarily occurs as masses in the abdomen. Other areas affected may include the lymph nodes, the lining of the abdomen, diaphragm, spleen, liver, chest wall, skull, spinal cord, large intestine, small intestine, bladder, brain, lungs, testicles, ovaries, and the pelvis. Reported sites of metastatic spread include the liver, lungs, lymph nodes, brain, skull, and bones. It is characterized by the EWS-WT1 fusion protein.

<span class="mw-page-title-main">Central neurogenic hyperventilation</span> Abnormal pattern of breathing

Central neurogenic hyperventilation (CNH) is an abnormal pattern of breathing characterized by deep and rapid breaths at a rate of at least 25 breaths per minute. Increasing irregularity of this respiratory rate generally is a sign that the patient will enter into coma. CNH is unrelated to other forms of hyperventilation, like Kussmaul's respirations. CNH is the human body's response to reduced carbon dioxide levels in the blood. This reduction in carbon dioxide is caused by contraction of cranial arteries from damage caused by lesions in the brain stem. However, the mechanism by which CNH arises as a result from these lesions is still very poorly understood. Current research has yet to provide an effective means of treatment for the rare number of patients who are diagnosed with this condition.

<span class="mw-page-title-main">Neurofibromatosis type II</span> Type of neurofibromatosis disease

Neurofibromatosis type II is a genetic condition that may be inherited or may arise spontaneously, and causes benign tumors of the brain, spinal cord, and peripheral nerves. The types of tumors frequently associated with NF2 include vestibular schwannomas, meningiomas, and ependymomas. The main manifestation of the condition is the development of bilateral benign brain tumors in the nerve sheath of the cranial nerve VIII, which is the "auditory-vestibular nerve" that transmits sensory information from the inner ear to the brain. Besides, other benign brain and spinal tumors occur. Symptoms depend on the presence, localisation and growth of the tumor(s). Many people with this condition also experience vision problems. Neurofibromatosis type II is caused by mutations of the "Merlin" gene, which seems to influence the form and movement of cells. The principal treatments consist of neurosurgical removal of the tumors and surgical treatment of the eye lesions. Historically the underlying disorder has not had any therapy due to the cell function caused by the genetic mutation.

<span class="mw-page-title-main">Pilocytic astrocytoma</span> Medical condition

Pilocytic astrocytoma is a brain tumor that occurs most commonly in children and young adults. They usually arise in the cerebellum, near the brainstem, in the hypothalamic region, or the optic chiasm, but they may occur in any area where astrocytes are present, including the cerebral hemispheres and the spinal cord. These tumors are usually slow growing and benign, corresponding to WHO malignancy grade 1.

<span class="mw-page-title-main">Blastoma</span> Type of cancer arising from precursor cells

A blastoma is a type of cancer, more common in children, that is caused by malignancies in precursor cells, often called blasts. Examples are nephroblastoma, medulloblastoma, and retinoblastoma. The suffix -blastoma is used to imply a tumor of primitive, incompletely differentiated cells, e.g., chondroblastoma is composed of cells resembling the precursor of chondrocytes.

A brain stem tumor is a tumor in the part of the brain that connects to the spinal cord.

<span class="mw-page-title-main">Brain metastasis</span> Cancer that has metastasized (spread) to the brain from another location in the body

A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, as primary tumors that originate in the brain are less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur months or even years after the original or primary cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments allow patients to live months and sometimes years after the diagnosis.

Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are very dangerous and life-threatening. Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade astrocytoma/oligodendroglioma are among the worst. In these cases, untreated survival usually amounts to only a few months, and survival with current radiation and chemotherapy treatments may extend that time from around a year to a year and a half, possibly two or more, depending on the patient's condition, immune function, treatments used, and the specific type of malignant brain neoplasm. Surgery may in some cases be curative, but, as a general rule, malignant brain cancers tend to regenerate and emerge from remission easily, especially highly malignant cases. In such cases, the goal is to excise as much of the mass and as much of the tumor margin as possible without endangering vital functions or other important cognitive abilities. The Journal of Neuro-Oncology is the longest continuously published journal in the field and serves as a leading reference to those practicing in the area of neuro-oncology.

<span class="mw-page-title-main">Fibrillary astrocytoma</span> Type of brain tumor

Fibrillary astrocytomas are a group of primary slow-growing brain tumors that typically occur in adults between the ages of 20 and 50.

<span class="mw-page-title-main">Plus Therapeutics</span> U.S. healthcare company

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. The company is headquartered in Austin, Texas, United States.

<span class="mw-page-title-main">Diffuse midline glioma</span> Highly aggressive brain tumor, mostly found in children

Diffuse midline glioma, H3 K27-altered (DMG) is a fatal tumour that arises in midline structures of the brain, most commonly the brainstem, thalamus and spinal cord. When located in the pons it is also known as diffuse intrinsic pontine glioma (DIPG).

Ren Michael Pedersen is an advocate for children's brain cancer research.

Clinica 0-19 is a medical clinic in Monterrey, Mexico that claims to treat diffuse intrinsic pontine glioma (DIPG). Although DIPG is currently regarded as one of the most devastating pediatric cancers, with a survival rate of <1% over five years, the clinic states that their treatment, which can cost hundreds of thousands of dollars, has resulted in some patients no longer having any evidence of disease. However, there is no credible evidence to support their claims and at least some of their patients were found to have tumor growth a few months later. Oncologists and others have criticized the clinic's lead doctors, Alberto Siller and Alberto Garcia, for their lack of transparency, for not publishing their treatment protocol or survival rates, for the high costs of treatment, and for discouraging their patients from using radiation therapy.

<span class="mw-page-title-main">Michelle Monje</span> American neurologist and researcher

Michelle Leigh Monje-Deisseroth is a neuroscientist and neuro-oncologist. She is a professor of neurology at Stanford University and an investigator with the Howard Hughes Medical Institute. She develops new treatments for diffuse intrinsic pontine glioma.

<span class="mw-page-title-main">Anaplastic oligodendroglioma</span> Human brain tumor

Anaplastic oligodendroglioma is a neuroepithelial tumor which is believed to originate from oligodendrocytes, a cell type of the glia. In the World Health Organization (WHO) classification of brain tumors, anaplastic oligodendrogliomas are classified as grade III. In the course of the disease, it can degenerate into highly malignant oligodendroglioma, grade IV. The vast majority of oligodendrogliomas occur sporadically, without a confirmed cause and without inheritance within a family.

References

  1. Landolfi, Joseph (30 June 2009). "Brainstem Gliomas". eMedicine. Archived from the original on 31 July 2010. Retrieved 15 August 2010.
  2. Salmaggi A, Fariselli L, Milanesi I, et al. (February 2008). "Natural history and management of brainstem gliomas in adults. A retrospective Italian study". J. Neurol. 255 (2): 171–7. doi:10.1007/s00415-008-0589-0. PMID   18293027. S2CID   22436880.
  3. 1 2 "Childhood Brain Stem Glioma Treatment (PDQ®)" (Patient version). National Cancer Institute. 20 January 2023. Archived from the original on 19 January 2024. Retrieved 19 January 2024.
  4. Broniscer A, Laningham FH, Kocak M, et al. (March 2006). "Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma". Cancer. 106 (6): 1364–71. doi:10.1002/cncr.21749. PMID   16463390. S2CID   23959929.
  5. "Decadron Phosphate 2392-39-4", Sax's Dangerous Properties of Industrial Materials, Hoboken, NJ, USA: John Wiley & Sons, Inc., pp. 1–2, 2012-10-15, doi:10.1002/0471701343.sdp33110, ISBN   978-0-471-47662-7
  6. Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP (January 2003). "A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952". Neuro-Oncology. 5 (1): 8–13. doi:10.1093/neuonc/5.1.8. PMC   1920667 . PMID   12626128. Archived from the original on 2009-04-17.
  7. "Milestone Clinical Trial for DIPG Approved". Weill Cornell Brain and Spine Center. Archived from the original on 2013-05-18. Retrieved 2013-05-26.
  8. "Error". cancer.gov.[ permanent dead link ]
  9. "Gene sequencing project discovers mutations tied to deadly brain tumors in young children". medicalxpress.com. Archived from the original on 2014-04-13. Retrieved 2014-04-11.
  10. "Hair Loss Caused by Stress and Trauma". surethik.com. Archived from the original on 2017-07-04. Retrieved 2015-11-22.
  11. "New system uses nanodiamonds to deliver chemotherapy drugs directly to brain tumors". phys.org. Archived from the original on 2014-04-13. Retrieved 2014-04-11.
  12. "Researchers identify a switch that controls growth of most aggressive brain tumor cells". phys.org.
  13. "Genetic flaw may hold key to deadly childhood brain tumour". medicalxpress.com. Archived from the original on 2014-04-13. Retrieved 2014-04-11.
  14. ""Uni Strand" Strip method". surehair.com. Archived from the original on 2015-11-23.
  15. European Patent Office. "EPO - Fighting cancer with nanotechnology". epo.org. Archived from the original on 2014-04-13. Retrieved 2014-04-11.
  16. just host. "Welcome justonemoreday.org - Justhost.com". justonemoreday.org. Archived from the original on 2018-10-06. Retrieved 2013-05-26.